BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers

Journal of the National Cancer Institute

Volumn 108, Issue 2, 2016, Pages

  Meeks, Huong D ^a   Song, Honglin ^b   Michailidou, Kyriaki ^b   Bolla, Manjeet K ^b   Dennis, Joe ^b   Wang, Qin ^b   Barrowdale, Daniel ^b   Frost, Debra ^b   McGuffog, Lesley ^b   Ellis, Steve ^b   Feng, Bingjian ^c   Buys, Saundra S ^c   Hopper, John L ^d   Southey, Melissa C ^e   Tesoriero, Andrea ^e   James, Paul A ^e,f   Bruinsma, Fiona ^g   Campbell, Ian G ^e   Broeks, Annegien ⁱ   Schmidt, Marjanka K ⁱ   Hogervorst, Frans B L ^j   Beckman, Matthias W ^k   Fasching, Peter A ^k,l   Fletcher, Olivia ^m   Johnson, Nichola ^m   Sawyer, Elinor J ⁿ   Riboli, Elio ^o   Banerjee, Susana ^p   Menon, Usha ^q   Tomlinson, Ian ^r   Burwinkel, Barbara ^s   Hamann, Ute ^s   Marme, Frederik ^t   Rudolph, Anja ^s   Janavicius, Ramunas ^u   Tihomirova, Laima ^v   Tung, Nadine ^w   Garber, Judy ^x   Cramer, Daniel ^y   Terry, Kathryn L ^y   Poole, Elizabeth M ^z,aa   Tworoger, Shelley S ^z,aa   Dorfling, Cecilia M ^ab   Van Rensburg, Elizabeth J ^ab   Godwin, Andrew K ^ac   Guénel, Pascal ^ad,ae   Truong, Thérèse ^ad,ae   Stoppa Lyonnet, Dominique ^af,ag,ah   Damiola, Francesca ^ai   Mazoyer, Sylvie ^ai   Sinilnikova, Olga M ^ai,aj   Isaacs, Claudine ^ak   Maugard, Christine ^al   Bojesen, Stig E ^am,an   Flyger, Henrik ^an   Gerdes, Anne Marie ^ao   Hansen, Thomas V O ^ao   Jensen, Allen ^ap   Kjaer, Susanne K ^ap,aq   Hogdall, Claus ^aq   Hogdall, Estrid ^ap,aq   Pedersen, Inge Sokilde ^ar   Thomassen, Mads ^as   Benitez, Javier ^at,au   González Neira, Anna ^at   Osorio, Ana ^at,au   Hoya, Miguel De La ^av   Segura, Pedro Perez ^av   Diez, Orland ^aw   Lazaro, Conxi ^ax   Brunet, Joan ^ay   Anton Culver, Hoda ^az   Eunjung, Lee ^ba   John, Esther M ^bb   Neuhausen, Susan L ^bc   Ding, Yuan Chun ^bc   Castillo, Danielle ^bc   Weitzel, Jeffrey N ^bc   Ganz, Patricia A ^l   Nussbaum, Robert L ^bd   Chan, Salina B ^be   Karlan, Beth Y ^bf   Lester, Jenny ^bf   Wu, Anna ^ba   Gayther, Simon ^ba   Ramus, Susan J ^ba   Sieh, Weiva ^bg   Whittermore, Alice S ^bg   Monteiro, Alvaro N A ^bh   Phelan, Catherine M ^bh   Terry, Mary Beth ^bi   Piedmonte, Marion ^bj   Offit, Kenneth ^bk   Robson, Mark ^bk   Levine, Douglas ^bk   Moysich, Kirsten B ^bj   Cannioto, Rikki ^bj   Olson, Sara H ^b,bk   Daly, Mary B ^bl   Nathanson, Katherine L ^bm   Domchek, Susan M ^bm   Lu, Karen H ^bn   Liang, Dong ^bo   Hildebrant, Michelle A T ^bn   Ness, Roberta ^bp   Modugno, Francesmary ^bq,br,bs   Pearce, Leigh ^ba,bt   Goodman, Marc T ^bf   Thompson, Pamela J ^bf   Brenner, Hermann ^s   Butterbach, Katja ^bu   Meindl, Alfons ^bv   Hahnen, Eric ^bw,bx   Wappenschmidt, Barbara ^bw,bx   Brauch, Hiltrud ^s,by,bz   Brüning, Thomas ^ca   Blomqvist, Carl ^cb   Khan, Sofia ^cb   Nevanlinna, Heli ^cb   Pelttari, Liisa M ^cb   Aittomäki, Kristiina ^cb   Butzow, Ralf ^cb   Bogdanova, Natalia V ^cc   Dörk, Thilo ^cc   Lindblom, Annika ^cd   Margolin, Sara ^cd   Rantala, Johanna ^ce   Kosma, Veli Matti ^cf,cg   Mannermaa, Arto ^cf,cg   Lambrechts, Diether ^ch,ci   Neven, Patrick ^cj   Claes, Kathleen B M ^ck   Van Maerken, Tom ^ck   Chang Claude, Jenny ^s   Flesch Janys, Dieter ^cl   Heitz, Florian ^cm,cn   Varon Mateeva, Raymonda ^co   Peterlongo, Paolo ^cp   Radice, Paolo ^cq   Viel, Alessandra ^cr   Barile, Monica ^cs   Peissel, Bernard ^cq   Manoukian, Siranoush ^cq   Montagna, Marco ^ct   Oliani, Cristina ^cu   Peixoto, Ana ^cv   Teixeira, Manuel R ^cv,cw   Collavoli, Anita ^cx   Hallberg, Emily ^cy   Olson, Janet E ^cy   Goode, Ellen L ^cy   Hart, Steven N ^cy   Shimelis, Hermela ^cy   Cunningham, Julie M ^cy   Giles, Graham G ^d,g   Milne, Roger L ^d,g   Healey, Sue ^h   Tucker, Kathy ^cz   Haiman, Christopher A ^ba   Henderson, Brian E ^ba   Goldberg, Mark S ^da,db   Tischkowitz, Marc ^db,dc   Simard, Jacques ^dd   Soucy, Penny ^dd   Eccles, Diana M ^de   Le, Nhu ^df   Borresen Dale, Anne Lise ^dg,dh   Kristensen, Vessela ^dg,dh,di   Salvesen, Helga B ^dj,dk   Bjorge, Line ^dj,dk   Bandera, Elisa V ^dl   Risch, Harvey ^dm   Zheng, Wei ^dn   Beeghly Fadiel, Alicia ^dn   Cai, Hui ^dn   Pylkäs, Katri ^do,dp   Tollenaar, Robert A E M ^dq   Ouweland, Ans M W Van Der ^dq   Andrulis, Irene L ^dr,ds   Knight, Julia A ^dr,dt   Narod, Steven ^dt   Devilee, Peter ^du   Winqvist, Robert ^do,dp   Figueroa, Jonine ^dv   Greene, Mark H ^dv   Mai, Phuong L ^dv   Loud, Jennifer T ^dv   García Closas, Montserrat ^m   Schoemaker, Minouk J ^m   Czene, Kamila ^cd   Darabi, Hatef ^cd   McNeish, Iain ^dw   Siddiquil, Nadeem ^dx   Glasspool, Rosalind ^dy   Kwong, Ava ^dz,ea   Park, Sue K ^eb   Teo, Soo Hwang ^ec   Yoon, Sook Yee ^ec,ed   Matsuo, Keitaro ^ee   Hosono, Satoyo ^ee   Woo, Yin Ling ^ed   Gao, Yu Tang ^ef   Foretova, Lenka ^eg   Singer, Christian F ^eh   Rappaport Feurhauser, Christine ^eh   Friedman, Eitan ^ei   Laitman, Yael ^ei   Rennert, Gad ^ej   Imyanitov, Evgeny N ^ek   Hulick, Peter J ^el   Olopade, Olufunmilayo I ^em   Senter, Leigha ^en   Olah, Edith ^eo   Doherty, Jennifer A ^ep   Schildkraut, Joellen ^eq,er   Koppert, Linetta B ^dq   Kiemeney, Lambertus A ^es   Massuger, Leon F A G ^et   Cook, Linda S ^eu   Pejovic, Tanja ^ev   Li, Jingmei ^cd   Borg, Ake ^ew   Öfverholm, Anna ^ex   Rossing, Mary Anne ^ey   Wentzensen, Nicolas ^dv   Henriksson, Karin ^ez   Cox, Angela ^fa   Cross, Simon S ^fa   Pasini, Barbara J ^b   Shah, Mitul ^b   Kabisch, Maria ^s   Torres, Diana ^s,fb   Jakubowska, Anna ^fc   Lubinski, Jan ^fc   Gronwald, Jacek ^fc   Agnarsson, Bjarni A ^fd   Kupryjanczyk, Jolanta ^fe   Moes Sosnowska, Joanna ^fe   Fostira, Florentia ^ff   Konstantopoulou, Irene ^ff   Slager, Susan ^cx   Jones, Michael ^m   Antoniou, Antonis C ^b   Berchuck, Andrew ^eq   Swerdlow, Anthony ^m   Chenevix Trench, Georgia ^h   Dunning, Alison M ^b   Pharoah, Paul D P ^b   Hall, Per ^cd   Easton, Douglas F ^b   Couch, Fergus J ^cy   Spurdle, Amanda B ^z   Goldgar, David E ^a,c   more..

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF UTAH   (United States)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f PETER MACCALLUM CANCER CENTRE   (Australia)

^g CANCER EPIDEMIOLOGY CENTRE   (Australia)

^h QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

ⁱ ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^j NETHERLANDS CANCER INSTITUTE   (Netherlands)

^k UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m INSTITUTE OF CANCER RESEARCH   (United Kingdom)

ⁿ GUY S HOSPITAL   (United Kingdom)

^o IMPERIAL COLLEGE LONDON   (United Kingdom)

^p INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^q UNIVERSITY COLLEGE LONDON   (United Kingdom)

^r UNIVERSITY OF OXFORD   (United Kingdom)

^s GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^t UNIVERSITY OF HEIDELBERG   (Germany)

^u State Research Institute Centre for Innovative Medicine   (Lithuania)

^v LATVIAN BIOMEDICAL RESEARCH AND STUDY CENTRE   (Latvia)

^w BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^x DANA FARBER CANCER INSTITUTE   (United States)

^y BRIGHAM AND WOMEN S HOSPITAL   (United States)

^z HARVARD MEDICAL SCHOOL   (United States)

^aa HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^ab UNIVERSITY OF PRETORIA   (South Africa)

^ac UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^ad NATIONAL INSTITUTES OF HEALTH   (United States)

^ae UNIVERSITÉ PARIS SACLAY   (France)

^af INSTITUT CURIE   (France)

^ag INSTITUT CURIE   (France)

^ah UNIVERSITÉ PARIS DESCARTES   (France)

^ai CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^aj CENTRE LÉON BÉRARD   (France)

^ak GEORGETOWN UNIVERSITY   (United States)

^al HÔPITAL CIVIL   (France)

^am UNIVERSITY OF COPENHAGEN   (Denmark)

^an GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^ao Rigshospitalet   (Denmark)

^ap DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^aq UNIVERSITY OF COPENHAGEN   (Denmark)

^ar AALBORG UNIVERSITY HOSPITAL   (Denmark)

^as ODENSE UNIVERSITY HOSPITAL   (Denmark)

^at Centro Nacional de Investigaciones Oncológicas   (Spain)

^au CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^av HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^aw VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^ax BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^ay CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^az UNIVERSITY OF CALIFORNIA   (United States)

^ba UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^bb CANCER PREVENTION INSTITUTE OF CALIFORNIA   (United States)

^bc CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^bd UNIVERSITY OF CALIFORNIA   (United States)

^be UNIVERSITY OF CALIFORNIA   (United States)

^bf CEDARS SINAI MEDICAL CENTER   (United States)

^bg STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^bh H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^bi Memorial Sloan Kettering Cancer Center ^*  (United States)

^bj ROSWELL PARK CANCER INSTITUTE   (United States)

^bk MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^bl FOX CHASE CANCER CENTER   (United States)

^bm UNIVERSITY OF PENNSYLVANIA   (United States)

^bn UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^bo TEXAS SOUTHERN UNIVERSITY   (United States)

^bp UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^bq UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^br UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^bs UNIVERSITY OF PITTSBURGH   (United States)

^bt UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^bu UNIVERSITY OF WARWICK   (United Kingdom)

^bv TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^bw University of Cologne   (Germany)

^bx UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^by DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^bz UNIVERSITY OF TÜBINGEN   (Germany)

^ca INSTITUT DER RUHR UNIVERSITÄT BOCHUM IPA   (Germany)

^cb UNIVERSITY OF HELSINKI   (Finland)

^cc HANNOVER MEDICAL SCHOOL   (Germany)

^cd KAROLINSKA INSTITUTE   (Sweden)

^ce KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^cf UNIVERSITY OF EASTERN FINLAND   (Finland)

^cg KUOPIO UNIVERSITY HOSPITAL   (Finland)

^ch DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^ci UNIVERSITY OF LEUVEN   (Belgium)

^cj UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^ck GHENT UNIVERSITY HOSPITAL   (Belgium)

^cl UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^cm KLINIKEN ESSEN MITTE   (Germany)

^cn DR HORST SCHMIDT KLINIKEN   (Germany)

^co CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^cp FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^cq NATIONAL CANCER INSTITUTE   (Italy)

^cr CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^cs EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^ct VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^cu UOC di Oncologia   (Italy)

^cv Portugese Oncology Institute   (Portugal)

^cw UNIVERSITY OF PORTO   (Portugal)

^cx UNIVERSITY HOSPITAL OF PISA   (Italy)

^cy MAYO CLINIC   (United States)

^cz PRINCE OF WALES HOSPITAL   (Australia)

^da ROYAL VICTORIA HOSPITAL   (Canada)

^db MCGILL UNIVERSITY   (Canada)

^dc UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^dd Université Laval   (Canada)

^de UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^df BRITISH COLUMBIA CANCER AGENCY   (Canada)

^dg OSLO UNIVERSITY HOSPITAL   (Norway)

^dh UNIVERSITY OF OSLO   (Norway)

^di OSLO UNIVERSITY HOSPITAL   (Norway)

^dj HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^dk UNIVERSITY OF BERGEN   (Norway)

^dl RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^dm YALE UNIVERSITY   (United States)

^dn VANDERBILT INGRAM CANCER CENTER   (United States)

^do UNIVERSITY OF OULU   (Finland)

^dp Laboratory of Cancer Genetics and Tumor Biology   (Finland)

^dq ERASMUS MEDICAL CENTER   (Netherlands)

^dr MOUNT SINAI HOSPITAL   (Canada)

^ds UNIVERSITY OF TORONTO   (Canada)

^dt UNIVERSITY OF TORONTO   (Canada)

^du LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^dv NATIONAL CANCER INSTITUTE   (United States)

^dw UNIVERSITY OF GLASGOW   (United Kingdom)

^dx GLASGOW ROYAL INFIRMARY   (United Kingdom)

^dy IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^dz HONG KONG SANATORIUM AND HOSPITAL   (Hong Kong)

^ea UNIVERSITY OF HONG KONG   (Hong Kong)

^eb Seoul National University College of Medicine   (South Korea)

^ec CANCER RESEARCH INITIATIVES FOUNDATION   (Malaysia)

^ed UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

^ee AICHI CANCER CENTER HOSPITAL   (Japan)

^ef SHANGHAI CANCER INSTITUTE   (China)

^eg MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^eh UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^ei GERTNER INSTITUTE FOR EPIDEMIOLOGY AND HEALTH POLICY RESEARCH   (Israel)

^ej CLALIT HEALTH SERVICES   (Israel)

^ek N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^el NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^em UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^en OHIO STATE UNIVERSITY   (United States)

^eo NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^ep DARTMOUTH MEDICAL SCHOOL   (United States)

^eq DUKE UNIVERSITY MEDICAL CENTER   (United States)

^er DUKE CANCER INSTITUTE   (United States)

^es RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^et RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^eu UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^ev OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^ew LUND UNIVERSITY   (Sweden)

^ex SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^ey Fred Hutchinson Cancer Research Center   (United States)

^ez LUND UNIVERSITY HOSPITAL   (Sweden)

^fa UNIVERSITY OF SHEFFIELD   (United Kingdom)

^fb PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

^fc POMERANIAN MEDICAL UNIVERSITY   (Poland)

^fd LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^fe INSTITUTE OF ONCOLOGY   (Poland)

^ff INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ESTROGEN RECEPTOR; BRCA2 PROTEIN, HUMAN; LYSINE; STOP CODON;

ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; STOP CODON; TRIPLE NEGATIVE BREAST CANCER; ADULT; AGED; BREAST TUMOR; FEMALE; GENETIC PREDISPOSITION; GENETICS; MALE; MIDDLE AGED; ODDS RATIO; OVARY TUMOR; PATHOLOGY; PROSTATE TUMOR; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; TUMOR INVASION;

ADULT; AGED; BRCA2 PROTEIN; BREAST NEOPLASMS; CODON, TERMINATOR; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; LOGISTIC MODELS; LYSINE; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; ODDS RATIO; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS;

EID: 84962488384     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv315     Document Type: Article

References (54)

1. Brohet RM, Velthuizen ME, Hogervorst FB, et al. Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations. J Med Genet. 2014;51(2):98-107.
2. Tavtigian SV, Simard J, Rommens J, et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet. 1996;12(3):333-337.
3. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378(6559):789-792.
4. Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994;265(5181):2088-2090.
5. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117-1130.
6. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;62(3):676-689.
7. Moran A, O'Hara C, Khan S, et al. Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Fam Cancer. 2012;11(2):235-242.
8. Risch HA, McLaughlin JR, Cole DE, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst. 2006;98(23):1694-1706.
9. Thompson D, Szabo CI, Mangion J, et al. Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium. Proc Natl Acad Sci U S A. 2002;99(2):827-831.
10. Iqbal J, Ragone A, Lubinski J, et al. The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2012;107(12):2005-2009.
11. Mocci E, Milne RL, Mendez-Villamil EY, et al. Risk of pancreatic cancer in breast cancer families from the breast cancer family registry. Cancer Epidemiol Biomarkers Prev. 2013;22(5):803-811.
12. Mazoyer S, Dunning AM, Serova O, et al. A polymorphic stop codon in BRCA2. Nat Genet. 1996;14(3):253-254.
13. Claes K, Poppe B, Machackova E, et al. Differentiating pathogenic mutations from polymorphic alterations in the splice sites of BRCA1 and BRCA2. Genes Chromosomes Cancer. 2003;37(3):314-320.
14. Haraldsson K, Loman N, Zhang QX, et al. BRCA2 germ-line mutations are frequent in male breast cancer patients without a family history of the disease. Cancer Res. 1998;58(7):1367-1371.
15. Krainer M, Silva-Arrieta S, FitzGerald MG, et al. Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer. N Engl J Med. 1997;336(20):1416-1421.
16. Wang Y, McKay JD, Rafnar T, et al. Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer. Nat Genet. 2014;46(7):736-741.
17. Michailidou K, Hall P, Gonzalez-Neira A, et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet. 2013;45(4):353-361, 361e1-361e2.
18. Delahaye-Sourdeix M, Anantharaman D, Timofeeva MN, et al. A rare truncating BRCA2 variant and genetic susceptibility to squamous cell cancers of upper aerodigestive tract. J Natl Cancer Inst Monogr. 2014.
19. Higgs JE, Harkness EF, Bowers NL, et al. The BRCA2 polymorphic stop codon: stuff or nonsense? J Med Genet. 2015;52(9):642-645.
20. Sakoda LC, Jorgenson E, Witte JS. Turning of COGS moves forward findings for hormonally mediated cancers. Nat Genet. 2013;45(4):345-348.
21. Gaudet MM, Kuchenbaecker KB, Vijai J, et al. Identification of a BRCA2- specific modifier locus at 6p24 related to breast cancer risk. PLoS Genet. 2013;9(3):e1003173.
22. Williams RL. A note on robust variance estimation for cluster-correlated data. Biometrics. 2000;56(2):645-646.
23. R Development Core Team. R: A language and environment for statistical computing. In. Vienna, Austria: R Foundation for Statistical Computing; 2010.
24. Guidugli L, Pankratz VS, Singh N, et al. A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity. Cancer Res. 2013;73(1):265-275.
25. Pharoah PD, Tsai YY, Ramus SJ, et al. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet. 2013;45(4):362-370, 370e1-370e2.
26. Eeles RA, Olama AA, Benlloch S, et al. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet. 2013;45(4):385-391, 391e1-391e2.
27. International HapMap C. A haplotype map of the human genome. Nature. 2005;437(7063):1299-1320.
28. Martin ST, Matsubayashi H, Rogers CD, et al. Increased prevalence of the BRCA2 polymorphic stop codon K3326X among individuals with familial pancreatic cancer. Oncogene. 2005;24(22):3652-3656.
29. Atchley DP, Albarracin CT, Lopez A, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol. 2008;26(26):4282-4288.
30. Eisinger F, Stoppa-Lyonnet D, Longy M, et al. Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res. 1996;56(3):471-474.
31. Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2003;95(19):1482-1485.
32. Karp SE, Tonin PN, Begin LR, et al. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer. 1997;80(3):435-441.
33. Lakhani SR, Van De Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 2002;20(9):2310-2318.
34. Quenneville LA, Phillips KA, Ozcelik H, et al. HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry. Cancer. 2002;95(10):2068-2075.
35. Robson M, Gilewski T, Haas B, et al. BRCA-associated breast cancer in young women. J Clin Oncol. 1998;16(5):1642-1649.
36. Shih Ie M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164(5):1511-1518.
37. Risch HA, Marrett LD, Jain M, et al. Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study. Am J Epidemiol. 1996;144(4):363-372.
38. Landen CN Jr, Birrer MJ, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol. 2008;26(6):995-1005.
39. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70.
40. van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, et al. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet. 2005;42(9):711-719.
41. Consortium BCL. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999;91(15):1310-1316.
42. Joenje H, Patel KJ. The emerging genetic and molecular basis of Fanconi anaemia. Nat Rev Genet. 2001;2(6):446-457.
43. Taniguchi T, D'Andrea AD. Molecular pathogenesis of Fanconi anemia: recent progress. Blood 2006;107(11):4223-33.
44. Atanassov BS, Barrett JC, Davis BJ. Homozygous germ line mutation in exon 27 of murine Brca2 disrupts the Fancd2-Brca2 pathway in the homologous recombination-mediated DNA interstrand cross-links' repair but does not affect meiosis. Genes Chromosomes Cancer. 2005;44(4):429-437.
45. Mizuta R, LaSalle JM, Cheng HL, et al. RAB22 and RAB163/mouse BRCA2: proteins that specifically interact with the RAD51 protein. Proc Natl Acad Sci U S A. 1997;94(13):6927-6932.
46. Pellegrini L, Venkitaraman A. Emerging functions of BRCA2 in DNA recombination. Trends Biochem Sci. 2004;29(6):310-316.
47. Pellegrini L, Yu DS, Lo T, et al. Insights into DNA recombination from the structure of a RAD51-BRCA2 complex. Nature. 2002;420(6913):287-293.
48. Shivji MK, Davies OR, Savill JM, et al. A region of human BRCA2 containing multiple BRC repeats promotes RAD51-mediated strand exchange. Nucleic Acids Res. 2006;34(14):4000-4011.
49. Wang X, Andreassen PR, D'Andrea AD. Functional interaction of monoubiquitinated FANCD2 and BRCA2/FANCD1 in chromatin. Mol Cell Biol. 2004;24(13):5850-5862.
50. McAllister KA, Bennett LM, Houle CD, et al. Cancer susceptibility of mice with a homozygous deletion in the COOH-terminal domain of the Brca2 gene. Cancer Res. 2002;62(4):990-994.
51. Antoniou AC, Sinilnikova OM, Simard J, et al. RAD51 135G - >C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet. 2007;81(6):1186-1200.
52. Breast Cancer Association C. Commonly studied single-nucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium. J Natl Cancer Inst. 2006;98(19):1382-1396.
53. Schildkraut JM, Goode EL, Clyde MA, et al. Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. Cancer Res. 2009;69(6):2349-2357.
54. Kote-Jarai Z, Easton DF, Stanford JL, et al. Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium. Cancer Epidemiol Biomarkers Prev. 2008;17(8):2052-2061.